Psyence Biomedical (PBM) EBITDA (2023 - 2025)
Psyence Biomedical (PBM) posted quarterly EBITDA of -$752618.0 for Q3 2025, down 1898.59% year-over-year from $41845.0 in Q3 2024, and down 1898.59% on a QoQ basis from $41845.0 in Q3 2024.
Psyence Biomedical (PBM) EBITDA (2023 - 2025) Analysis & Trends
Psyence Biomedical (PBM) has reported EBITDA for 3 consecutive years, with -$752618.0 the latest figure, recorded in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | -106.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.44 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 249.90 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.14 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.91 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 661.60 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 394.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 201.19 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -445.22 Mn |
| 10 | Psyence Biomedical | 1.72 Mn | 1.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -752,618.00 |
| Sep 30, 2024 | 41,845.00 |
| Mar 31, 2023 | -3.21 Mn |